IRIS
FUMAROLA, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.999
AS - Asia 4.002
EU - Europa 3.330
SA - Sud America 534
AF - Africa 217
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 13.094
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.900
SG - Singapore 1.345
CN - Cina 1.085
IT - Italia 966
VN - Vietnam 638
IE - Irlanda 433
BR - Brasile 415
FI - Finlandia 411
SE - Svezia 393
DE - Germania 296
HK - Hong Kong 285
BD - Bangladesh 169
FR - Francia 159
UA - Ucraina 133
ZA - Sudafrica 130
NL - Olanda 115
GB - Regno Unito 107
IN - India 105
TR - Turchia 87
RU - Federazione Russa 79
CA - Canada 59
AT - Austria 54
BE - Belgio 49
AR - Argentina 48
CI - Costa d'Avorio 41
KR - Corea 32
PL - Polonia 32
IQ - Iraq 31
JP - Giappone 29
ID - Indonesia 27
ES - Italia 25
MX - Messico 22
CZ - Repubblica Ceca 21
PK - Pakistan 21
CO - Colombia 20
EC - Ecuador 20
PH - Filippine 19
TH - Thailandia 17
PS - Palestinian Territory 12
VE - Venezuela 11
JO - Giordania 10
LT - Lituania 10
MA - Marocco 10
SA - Arabia Saudita 10
EG - Egitto 9
IR - Iran 9
UZ - Uzbekistan 8
KE - Kenya 7
AU - Australia 6
HU - Ungheria 6
LB - Libano 6
LU - Lussemburgo 6
MY - Malesia 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
KG - Kirghizistan 5
NP - Nepal 5
PY - Paraguay 5
SY - Repubblica araba siriana 5
BO - Bolivia 4
CH - Svizzera 4
CL - Cile 4
JM - Giamaica 4
MD - Moldavia 4
NZ - Nuova Zelanda 4
OM - Oman 4
PE - Perù 4
PT - Portogallo 4
QA - Qatar 4
RO - Romania 4
TN - Tunisia 4
TW - Taiwan 4
AZ - Azerbaigian 3
DZ - Algeria 3
PA - Panama 3
UY - Uruguay 3
AO - Angola 2
CY - Cipro 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
GA - Gabon 2
GE - Georgia 2
IL - Israele 2
KZ - Kazakistan 2
NI - Nicaragua 2
NO - Norvegia 2
SN - Senegal 2
TG - Togo 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
AM - Armenia 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
DM - Dominica 1
GR - Grecia 1
Totale 13.076
Salva come PNG Salva come JPEG
Città #
Singapore 738
Dallas 631
Ashburn 517
Dublin 433
San Jose 402
Chandler 392
Ann Arbor 338
Parma 290
Santa Clara 281
Hong Kong 265
Beijing 226
Ho Chi Minh City 180
Dearborn 155
Jacksonville 145
New York 139
Boardman 138
Hanoi 138
Los Angeles 125
Johannesburg 123
Shanghai 99
Munich 92
Council Bluffs 89
Hefei 88
Nanjing 85
Milan 80
Lauterbourg 75
Princeton 67
Izmir 65
Bremen 60
Chicago 52
Helsinki 50
Vienna 46
Abidjan 41
Nanchang 41
São Paulo 41
Buffalo 40
San Mateo 40
Bologna 38
Shenyang 37
Modena 35
Moscow 34
The Dalles 34
Wilmington 34
Brussels 31
Haiphong 31
Kunming 28
Columbus 27
Hebei 27
Da Nang 26
Toronto 26
Jinan 24
Marseille 24
Seattle 24
Tianjin 24
Frankfurt am Main 23
Seoul 23
Warsaw 23
Des Moines 22
Tokyo 22
Jakarta 21
London 21
Redmond 20
Turku 20
Stockholm 19
Denver 18
Nuremberg 17
Rome 17
Woodbridge 17
Manchester 16
Orem 16
Phoenix 16
Pune 15
Reggio Emilia 15
Amsterdam 14
Atlanta 14
Bari 14
Chennai 14
Guangzhou 14
Norwalk 14
Brescia 13
Changsha 13
Houston 13
Montreal 13
Poplar 13
Rio de Janeiro 13
Boston 12
Jiaxing 12
Neviano degli Arduini 12
Wayne 12
Brooklyn 11
Dhaka 11
Florence 11
Leawood 11
New Delhi 11
Verona 11
Baghdad 10
Biên Hòa 10
Fremont 10
Naples 10
Zhengzhou 10
Totale 7.998
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 350
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 264
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 251
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 247
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 244
Novel activity of a synthetic decapeptide against Toxoplasma gondii Tachyzoites 221
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 218
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 215
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 211
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 206
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 201
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 201
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 201
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 197
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 196
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 193
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 192
Characterization of gefitinib uptake in NSCLC cell lines 190
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 190
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 186
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 185
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 182
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 182
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 180
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 178
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 177
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 177
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 176
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 175
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 174
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 174
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 173
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 171
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 171
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 170
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 170
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 163
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 161
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 160
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 158
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 158
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 158
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 157
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 157
Synergistic activity of letrozole and sorafenib on breast cancer cells 147
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 147
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 147
Physico-chemical characterization and biological evaluation of two fibroin materials 145
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 139
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 136
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 134
Immunotherapeutic approaches in malignant pleural mesothelioma 134
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 134
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 133
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 132
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 132
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 130
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 128
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 128
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 127
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 126
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 124
Correction to: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells (Journal of Experimental & Clinical Cancer Research, (2018), 37, 1, (72), 10.1186/s13046-018-0741-3) 120
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 120
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 120
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 117
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 117
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 112
Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways 112
Pure anti-tumor effect of zoledronic acid in naive bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy" 111
Espressione Inducibile del gene FHIT in cellule di carcinoma polmonare 104
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 104
Effect of inducible FHIT and p53 expression on CALU-1 cell proliferation. 100
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 100
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 99
Targeting FGFR1 pathway in squamous cell lung cancer 98
Increased level of inducible HSP70 in cells exposed to electromagnetic fields. 97
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer 96
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 93
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 92
Studio dell’espressione del gene FHIT in cellule di carcinoma polmonare 89
New therapeutic strategies for malignant pleural mesothelioma 83
Evaluation of gefitinib maintenance in an EGFR-mutant NSCL cell line with acquired resistance 81
Effect of inducible Fhit and p53 expression in Calu-1 lung cancer cell line 79
Effect of constitutive expression of the fragile histidine triad gene on non small cell lung cancer 70
Effects of sorafenib on energy metabolism in breast cancer cells: Role of AMPK-mTORC1 signaling 40
null 31
Totale 13.269
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.328
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.328
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202140 0 0 0 0 0 0 0 0 0 0 0 40
2021/2022418 36 15 21 38 15 10 70 30 21 19 30 113
2022/20231.685 147 178 118 107 158 192 14 141 527 9 73 21
2023/2024800 38 49 28 43 54 156 67 68 33 45 89 130
2024/20252.438 87 110 167 178 249 259 177 124 283 199 205 400
2025/20265.520 427 480 797 537 721 275 590 172 710 388 264 159
Totale 13.269